Loading
A phase 2 trial in colorectal cancer, run by Ruijin Hospital, now recruiting.
Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC is a phase 2, interventional study registered as NCT07085169 by Ruijin Hospital, with a registry enrolment figure of 50 participants, started 2025-08-01 and due to reach its primary completion in 2027-08-01. Interventions recorded: Trifluridine/tipiracil (TAS-102) plus bevacizumab. Conditions listed: Colo-rectal Cancer; Third-line and Beyond Therapy; TAS 102; Bevacizumab. Primary outcome: 6-month progression-free survival rate. Colorectal eligibility wording from the registry: "histologically confirmed adenocarcinoma of the colon or rectum". Sites: China. No results are recorded here; the registry entry is the source.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.